Quick Answer
Immuneering Corp reported Research And Development Expense of $42.05 million for the year ending 2025.
- Immuneering Corp showed a decrease of -12.3% in Research And Development Expense from 2024 to 2025.
- This data is from Immuneering Corp's annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Immuneering Corp's Research And Development Expense has grown by 180.3%.
- Historical annual values: Fiscal year 2025: $42.05 million | Fiscal year 2024: $47.96 million | Fiscal year 2023: $41.62 million | Fiscal year 2022: $36.27 million | Fiscal year 2021: $26.54 million | Fiscal year 2020: $15.00 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: